331 related articles for article (PubMed ID: 36902474)
21. [Use of new inotropic agents in the treatment of acute cardiac failure].
Dhainaut JF
Ann Fr Anesth Reanim; 1988; 7(2):97-104. PubMed ID: 2896479
[TBL] [Abstract][Full Text] [Related]
22. Prevention of ventricular fibrillation, acute myocardial infarction (myocardial necrosis), heart failure, and mortality by bretylium: is ischemic heart disease primarily adrenergic cardiovascular disease?
Bacaner M; Brietenbucher J; LaBree J
Am J Ther; 2004; 11(5):366-411. PubMed ID: 15356432
[TBL] [Abstract][Full Text] [Related]
23. Present state of alpha- and beta-adrenergic drugs I. The adrenergic receptor.
Ahlquist RP
Am Heart J; 1976 Nov; 92(5):661-4. PubMed ID: 10722
[TBL] [Abstract][Full Text] [Related]
24. Sympathomimetic amines: potential clinical applications in ischemic heart disease.
Goldberg LI; Rajfer SI
Am Heart J; 1982 Apr; 103(4 Pt 2):724-9. PubMed ID: 6278912
[TBL] [Abstract][Full Text] [Related]
25. Beta-adrenoceptors in cardiac disease.
Brodde OE
Pharmacol Ther; 1993 Dec; 60(3):405-30. PubMed ID: 7915424
[TBL] [Abstract][Full Text] [Related]
26. Beta-blocking agents and positive inotropic agents in the therapy of chronic heart failure.
Erdmann E; Schwinger R; Böhm M
J Cardiovasc Pharmacol; 1990; 16 Suppl 5():S138-44. PubMed ID: 11527118
[TBL] [Abstract][Full Text] [Related]
27. Role of nitric oxide in the regulation of myocardial function.
Hare JM; Colucci WS
Prog Cardiovasc Dis; 1995; 38(2):155-66. PubMed ID: 7568904
[TBL] [Abstract][Full Text] [Related]
28. Do human cardiac beta-2 adrenoceptors play a (patho)physiological role in regulation of heart rate and/or contractility?
Brodde OE; Zerkowski HR
Basic Res Cardiol; 1989; 84 Suppl 1():135-44. PubMed ID: 2554871
[TBL] [Abstract][Full Text] [Related]
29. Ischemia-reperfusion injury changes the dynamics of Ca2+-contraction coupling due to inotropic drugs in isolated hearts.
Rhodes SS; Ropella KM; Camara AK; Chen Q; Riess ML; Pagel PS; Stowe DF
J Appl Physiol (1985); 2006 Mar; 100(3):940-50. PubMed ID: 16282437
[TBL] [Abstract][Full Text] [Related]
30. Structure activity relationships of N-substituted dopamine derivatives as agonists of the dopamine vascular and other cardiovascular receptors.
Kohli JD; Weder AB; Goldberg LI; Ginos JZ
J Pharmacol Exp Ther; 1980 May; 213(2):370-4. PubMed ID: 7365696
[No Abstract] [Full Text] [Related]
31. GRK2-mediated inhibition of adrenergic and dopaminergic signaling in right ventricular hypertrophy: therapeutic implications in pulmonary hypertension.
Piao L; Fang YH; Parikh KS; Ryan JJ; D'Souza KM; Theccanat T; Toth PT; Pogoriler J; Paul J; Blaxall BC; Akhter SA; Archer SL
Circulation; 2012 Dec; 126(24):2859-69. PubMed ID: 23124027
[TBL] [Abstract][Full Text] [Related]
32. Pharmacological bases for the use of dopamine and related drugs in the treatment of congestive heart failure.
Goldberg LI
J Cardiovasc Pharmacol; 1989; 14 Suppl 8():S21-8. PubMed ID: 2483439
[TBL] [Abstract][Full Text] [Related]
33. Dopamine: receptors and clinical applications.
Goldberg LI
Clin Physiol Biochem; 1985; 3(2-3):120-6. PubMed ID: 3159532
[TBL] [Abstract][Full Text] [Related]
34. Dose-dependent separation of dopaminergic and adrenergic effects of epinine in healthy volunteers.
Daul A; Elter-Schulz M; Poller U; Jockenhövel F; Pönicke K; Boomsma F; Man in't Veld AJ; Schäfes RF; Brodde OE
Naunyn Schmiedebergs Arch Pharmacol; 1995 Oct; 352(4):429-37. PubMed ID: 8532072
[TBL] [Abstract][Full Text] [Related]
35. Stimulation of hypertrophy of cultured neonatal rat heart cells through an alpha 1-adrenergic receptor and induction of beating through an alpha 1- and beta 1-adrenergic receptor interaction. Evidence for independent regulation of growth and beating.
Simpson P
Circ Res; 1985 Jun; 56(6):884-94. PubMed ID: 2988814
[TBL] [Abstract][Full Text] [Related]
36. Role of the beta 2 adrenoceptor in mediating positive inotropic activity in the failing heart and its relation to the hemodynamic actions of dopexamine hydrochloride.
Lang RM; Borow KM; Neumann A; Carroll JD; Weinert L; Murphy MB; Ghali J; Rajfer SI
Am J Cardiol; 1988 Aug; 62(5):46C-52C. PubMed ID: 2841838
[TBL] [Abstract][Full Text] [Related]
37. Effects of dopamine D1 and dopamine D2 receptor agonists on coronary and peripheral hemodynamics.
Zhao RR; Fennell WH; Abel FL
Eur J Pharmacol; 1990 Nov; 190(1-2):193-202. PubMed ID: 1981750
[TBL] [Abstract][Full Text] [Related]
38. The haemodynamic and myocardial effects of dopexamine: a new beta 2-adrenoceptor and dopaminergic agonist.
Jaski BE; Wijns W; Foulds R; Serruys PW
Br J Clin Pharmacol; 1986 Apr; 21(4):393-400. PubMed ID: 2871852
[TBL] [Abstract][Full Text] [Related]
39. Effects of dopamine on left ventricular afterload and contractile state in heart failure: relation to the activation of beta 1-adrenoceptors and dopamine receptors.
Rajfer SI; Borow KM; Lang RM; Neumann A; Carroll JD
J Am Coll Cardiol; 1988 Aug; 12(2):498-506. PubMed ID: 2839569
[TBL] [Abstract][Full Text] [Related]
40. Effects of dopamine on L-type Ca2+ current in single atrial and ventricular myocytes of the rat.
Zhao H; Matsuoka S; Fujioka Y; Noma A
Br J Pharmacol; 1997 Aug; 121(7):1247-54. PubMed ID: 9257900
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
